Pigmentary changes in a patient treated with imatinib

Journal of Drugs in Dermatology

Volumn 10, Issue 9, 2011, Pages 1062-1066

  Balagula, Yevgeniy ^a   Pulitzer, Melissa P ^a   Maki, Robert G ^a   Myskowski, Patricia L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE; FLUOCINONIDE; HYDROCORTISONE; IMATINIB; MELANIN; PREDNISONE; TRIAMCINOLONE;

ADULT; ARTICLE; BODY SURFACE; CASE REPORT; CELL INFILTRATION; DERMATOFIBROSARCOMA PROTUBERANS; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; EPIDERMIS; ERYTHEMA; HAIR COLOR; HISTIOCYTE; HUMAN; HUMAN TISSUE; HYPERPIGMENTATION; KERATINOCYTE; LYMPHOCYTE; MACULOPAPULAR RASH; MALE; MELANOPHAGE; MUCOSA INFLAMMATION; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PHYSICAL EXAMINATION; SIDE EFFECT; SKIN BIOPSY; SKIN BURNING SENSATION; SKIN MANIFESTATION; SKIN PRURITUS; STRATUM CORNEUM; THRUSH; TREATMENT OUTCOME; URTICARIA;

ADULT; ANTINEOPLASTIC AGENTS; DERMATOFIBROSARCOMA; FOLLOW-UP STUDIES; HAIR COLOR; HUMANS; HYPERPIGMENTATION; MALE; PIPERAZINES; PYRIMIDINES; SKIN PIGMENTATION;

EID: 80053330202     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037. (Pubitemid 32267972)
2. Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients. J Am Acad Dermatol. 2003;48:201-206. (Pubitemid 36232317)
3. Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol. 2004;15:358-359. (Pubitemid 38262643)
4. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937. (Pubitemid 34525471)
5. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21:1637-1647. (Pubitemid 46594119)
6. Hsiao LT, Chung HM, Lin JT, Chiou TJ, Liu JH, Fan FS, Wang WS, Yen CC, Chen PM. Stevens-Johnson syndrome after treatment with STI571: A case report. Br J Haematol. 2002;117:620-622. (Pubitemid 34539237)
7. Brouard MC, Prins C, Mach-Pascual S, Saurat JH. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia. Dermatology. 2001;203:57-59. (Pubitemid 32830533)
8. Pascual JC, Matarredona J, Miralles J, Conesa V, Borras-Blasco J. Oral and cutaneous lichenoid reaction secondary to imatinib: Report of two cases. Int J Dermatol. 2006;45:1471-1473 (Pubitemid 44869776)
9. Brazzelli V, Prestinari F, Roveda E, Barbagallo T, Bellani E, Vassallo C, Orlandi E, Passamonti F, Borroni G. Pityriasis rosea-like eruption during treatment with imatinib mesylate: Description of 3 cases. J Am Acad Dermatol. 2005;53(5 suppl 1):240S-243S.
10. Ayirookuzhi SJ, Ma L, Ramshesh P, Mills G. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia. Arch Dermatol. 2005;141:368-370. (Pubitemid 40365453)
11. Drummond A, Micallef-Eynaud P, Douglas WS, Hay I, Holyoake TL, Drummond MW. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). Br J Haematol. 2003;120:911-913. (Pubitemid 36315121)
12. Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2003;98:2483-2487. (Pubitemid 37466664)
13. Legros L, Cassuto JP, Ortonne JP. Imatinib mesilate (Glivec): A systemic depigmenting agent for extensive vitiligo? Br J Dermatol. 2005;153:691-692.
14. Singh N, Bakhshi S. Imatinib-induced dental hyperpigmentation in childhood chronic myeloid leukemia. J Pediatr Hematol Oncol. 2007;29:208-209. (Pubitemid 46673415)
15. McPherson T, Sherman V, Turner R. Imatinib-associated hyperpigmentation, a side effect that should be recognized. J Eur Acad Dermatol Venereol. 2009;23:82-83.
16. Prabhash K, Biswas G, Prasad N, Karant N, Sastry PS, Parikh PM. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia. Indian J Dermatol Venereol Leprol. 2006;72:63-64. (Pubitemid 43201350)
17. Alexandrescu DT, Dasanu CA, Farzanmehr H, Kauffman L. Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. Dermatol Online J. 2008;14:7.
18. Han H, Yu YY, Wang YH. Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors. J Am Acad Dermatol. 2008;59(suppl 5):80S-83S.
19. Etienne G, Cony-Makhoul P, Mahon FX. Imatinib mesylate and gray hair. N Engl J Med. 2002;347:446.
20. Alexeev V, Yoon K. Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol. 2006;126:1102-1110.
21. Grichnik JM, Burch JA, Burchette J, Shea CR. The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol. 1998;111:233-238. (Pubitemid 28354709)
22. Hachiya A, Sriwiriyanont P, Kobayashi T, Nagasawa A, Yoshida H, et al. Stem cell factor-KIT signalling plays a pivotal role in regulating pigmentation in mammalian hair. J Pathol. 2009;218:30-39.
23. Hemesath TJ, Price ER, Takemoto C, Badalian T, Fisher DE. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature. 1998;391:298-301. (Pubitemid 28099019)
24. Yin XY, Ren YQ, Yang S, Xu SX, Zhou FS, Du WH, Lin D, Wang PG, Zhang SM, Zhang XJ. A novel KIT missense mutation in one Chinese family with piebaldism. Arch Dermatol Res. 2009;301:387-389.
25. Richards KA, Fukai K, Oiso N, Paller AS. A novel KIT mutation results in piebaldism with progressive depigmentation. J Am Acad Dermatol. 2001;44:288-292. (Pubitemid 32175105)
26. Kitamura R, Tsukamoto K, Harada K, Shimizu A, Shimada S, Kobayashi T, Imokawa G. Mechanisms underlying the dysfunction of melanocytes in vitiligo epidermis: Role of SCF/KIT protein interactions and the downstream effector, MITF-M. J Pathol. 2004;202:463-475. (Pubitemid 38456165)
27. Cario-Andre M, Ardilouze L, Pain C, Gauthier Y, Mahon FX, Taieb A. Imatinib mesilate inhibits melanogenesis in vitro. Br J Dermatol. 2006;155:493-494. (Pubitemid 44050600)
28. Robson ME, Glogowski E, Sommer G, Antonescu CR, Nafa K, Maki RG, Ellis N, Besmer P, Brennan M, Offit K. Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Clin Cancer Res. 2004;10:1250-1254. (Pubitemid 38365214)
29. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:25-35. (Pubitemid 46630490)
30. Commo S, Gaillard O, Bernard BA. Human hair greying is linked to a specific depletion of hair follicle melanocytes affecting both the bulb and the outer root sheath. Br J Dermatol.2004;150:435-443. (Pubitemid 38446297)